Fatty Liver News and Research

Latest Fatty Liver News and Research

Study shows link between fructose and pancreatic cancer proliferation

Pancreatic cancers use the sugar fructose, very common in the Western diet, to activate a key cellular pathway that drives cell division, helping the cancer to grow more quickly, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found.

4 Aug 2010

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health to conduct a double blind, multi-center, study to evaluate the effects of obeticholic acid in patients with nonalcoholic steatohepatitis (NASH).

28 Jul 2010

UDCA fails to improve overall histology in NASH patients: Study

A study conducted by researchers at Johann Wolfgang Goethe University in Frankfurt, Germany found that high doses of ursodeoxycholic acid, suggested by some studies to have a beneficial effect on nonalcoholic steatohepatitis, does not improve overall histology in these patients. Full findings of this study are published in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

21 Jul 2010

Early markers for metabolic syndrome in youth

Melinda Sothern, PhD, CEP, Professor of Public Health and Director of Health Promotion at LSU Health Sciences Center New Orleans, will present evidence that supports relationships seen in adolescents between insulin sensitivity and fatty liver, belly fat, and total body fat and identifies additional potential early markers of insulin resistance and metabolic syndrome in healthy 7-9 year-old children, including fat in muscle cells, blood pressure, physical activity, and birth weight.

13 Jul 2010

Research findings could offer new approach to diabetes therapy, nutrition experts say

Nutrition experts at Oregon State University have essentially "cured" laboratory mice of mild, diet-induced diabetes by stimulating the production of a particular enzyme. The findings could offer a new approach to diabetes therapy, experts say, especially if a drug could be identified that would do the same thing, which in this case was accomplished with genetic manipulation.

13 Jul 2010

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.

7 Jul 2010

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

24 Jun 2010

Diet with high fructose, trans fats lead to fatty liver disease with scar tissue

Scientists at Cincinnati Children's Hospital Medical Center have discovered that a diet with high levels of fructose - levels equivalent to that in high fructose corn syrup - and of trans fats not only increases obesity, but also leads to significant fatty liver disease with scar tissue.

23 Jun 2010

Drinking coffee may help prevent diabetes, report scientists

Scientists are reporting new evidence that drinking coffee may help prevent diabetes and that caffeine may be the ingredient largely responsible for this effect. Their findings, among the first animal studies to demonstrate this apparent link, appear in ACS' bi-weekly Journal of Agricultural and Food Chemistry.

10 Jun 2010

NASH-induced cirrhosis is greater risk factor for HCC: Cleveland Clinic study

A study conducted by researchers at the Cleveland Clinic finds that patients suffering from cirrhosis preceded by nonalcoholic steatohepatitis are at an equal risk of developing hepatocellular carcinoma than those who develop cirrhosis resulting from hepatitis C virus. Results of this study appear in the June issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

26 May 2010

Study identifies potential noninvasive biomarkers in NAFLD, NASH using Metabolon's platform

Metabolon, Inc. announces a study published in the Metabolism Journal released in the paper on April 28, 2010, by Satish C. Kalhan.

17 May 2010

Obesity epidemic may be flattening out - still much to be done

The prevalence of childhood obesity might be stabilising in developed countries, but there is still much to be done to combat this major threat to health, according to a Seminar published on Online First and in an upcoming issue of The Lancet.

6 May 2010

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Raptor Pharmaceutical Corp., announced positive Phase 2a clinical trial results from its pilot study of delayed-release cysteamine bitartrate in 11 adolescent patients with non-alcoholic steatohepatitis, a progressive form of liver disease believed to affect 5% to 11% of the U.S. population. The results were presented at the Digestive Disease Week 2010 conference in New Orleans, LA on May 2, 2010.

3 May 2010

Health outcomes explored at DDW 2010

Non-alcoholic fatty liver disease, which may soon be the leading indication for liver transplant, is found to be significantly associated with worse transplant outcomes. In addition, a new tool for diagnosing NAFLD represents an alternative to liver biopsy, which is more expensive and prone to complications, and ultrasound and alfafeprotein blood test screening are an effective alternative to CT scan and MRI for patients with cirrhosis at high risk for hepatocellular cancer.

3 May 2010

Vitamin E effective in treating NASH: Study

Vitamin E has been shown effective in treating nonalcoholic steatohepatitis, an obesity-associated chronic liver disease that can lead to cirrhosis, liver cancer, and death. NASH also is related to or a part of type 2 diabetes, lipid disorders and cardiovascular disease.

3 May 2010

Daily intake of vitamin E may help improve fatty liver disease: Study

In an NIH-funded study published in the New England Journal of Medicine, research found that daily vitamin E improved the livers of patients who have a type of liver disease known as nonalcoholic steatohepatitis.

30 Apr 2010

Study: Cigarette smoking, fructose consumption can worsen NAFLD

Recent studies suggest that modifiable risk factors such as cigarette smoking and fructose consumption can worsen nonalcoholic fatty liver disease. With NAFLD, fat accumulates in the liver of overweight individuals despite drinking little alcohol, causing in some cases liver scarring that can lead to liver failure.

27 Apr 2010

ZenBio awarded Phase I SBIR grant to establish novel human cell-based models of NAFLD

ZenBio, Inc. announced that it has been awarded a Phase I SBIR grant to establish novel human cell-based models of non-alcoholic fatty liver disease (NAFLD) that will be useful for basic research and as a potential drug development platform. The project stems from recent efforts at ZenBio, Inc. to develop methods for differentiating adipose tissue derived progenitor cells into hepatocyte-like cells.

21 Apr 2010

Treatment with high dose UDCA no more effective for NASH: German study

Results of a German study presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria, have shown that overall, treatment with high dose (23-28mg/kg/d) ursodeoxycholic acid is no more effective than placebo in the treatment of non-alcoholic steatohepatitis, the most advanced form of non-alcoholic liver disease associated with cirrhosis of the liver.

17 Apr 2010

Obese children have stiffer arteries than leaner counterparts

Children with more body fat and less endurance than their fitter, leaner counterparts have stiffer arteries at a young age, Medical College of Georgia researchers said.

12 Apr 2010

Fatty Liver News and Research

Latest Fatty Liver News and Research

Study shows link between fructose and pancreatic cancer proliferation

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

UDCA fails to improve overall histology in NASH patients: Study

Early markers for metabolic syndrome in youth

Research findings could offer new approach to diabetes therapy, nutrition experts say

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Diet with high fructose, trans fats lead to fatty liver disease with scar tissue

Drinking coffee may help prevent diabetes, report scientists

NASH-induced cirrhosis is greater risk factor for HCC: Cleveland Clinic study

Study identifies potential noninvasive biomarkers in NAFLD, NASH using Metabolon's platform

Obesity epidemic may be flattening out - still much to be done

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Health outcomes explored at DDW 2010

Vitamin E effective in treating NASH: Study

Daily intake of vitamin E may help improve fatty liver disease: Study

Study: Cigarette smoking, fructose consumption can worsen NAFLD

ZenBio awarded Phase I SBIR grant to establish novel human cell-based models of NAFLD

Treatment with high dose UDCA no more effective for NASH: German study

Obese children have stiffer arteries than leaner counterparts

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Fatty Liver News and Research

Latest Fatty Liver News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in